{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:27:07Z","timestamp":1793845627560,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"crossref","award":["NRCT189\/2563"],"award-info":[{"award-number":["NRCT189\/2563"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00702-025-02914-2","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:32:16Z","timestamp":1743251536000},"page":"1673-1683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Comparative efficacy of Mucuna pruriens and conventional levodopa in Parkinson\u2019s disease: a randomized controlled trial on pharmacokinetics and clinical perspectives from Asia"],"prefix":"10.1007","volume":"132","author":[{"given":"Thanatat","family":"Boonmongkol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onanong","family":"Phokaewvarangkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sornkanok","family":"Vimolmangkang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitima","family":"Wattanavijitkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virunya","family":"Komenkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6901-2064","authenticated-orcid":false,"given":"Roongroj","family":"Bhidayasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"key":"2914_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ibneur.2024.05.011","volume":"17","author":"PO Abolarin","year":"2024","unstructured":"Abolarin PO, Amin A, Nafiu AB, Ogundele OM, Owoyele BV (2024) Optimization of Parkinson\u2019s disease therapy with plant extracts and nutrition\u2019s evolving roles. IBRO Neurosci Rep 17:1\u201312. https:\/\/doi.org\/10.1016\/j.ibneur.2024.05.011","journal-title":"IBRO Neurosci Rep"},{"issue":"2","key":"2914_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.parkreldis.2014.11.002","volume":"21","author":"MC Altavista","year":"2015","unstructured":"Altavista MC, Cassetta E, Brusa L, Viselli F, Denaro A, Ventriglia M, Pasqualetti P, Peppe A (2015) Wearing-off detection in clinical practice: the wearing off real practice key (WORK-PD) study in Parkinson\u2019s disease. Parkinsonism Relat Disord 21(2):95\u2013100. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.11.002","journal-title":"Parkinsonism Relat Disord"},{"key":"2914_CR3","unstructured":"ASEAN (2015) ASEAN Guidelines on Limits of Contaminants for Traditional Medicines. In: The 27th ACCSQ Traditional Medicines and Health Supplements Scientific Committee Meeting (ATSC), Kuala Lumpur, Malaysia"},{"issue":"1\u20132","key":"2914_CR4","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jns.2007.08.028","volume":"266","author":"R Bhidayasiri","year":"2008","unstructured":"Bhidayasiri R, Truong DD (2008) Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 266(1\u20132):204\u2013215. https:\/\/doi.org\/10.1016\/j.jns.2007.08.028","journal-title":"J Neurol Sci"},{"issue":"11","key":"2914_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1586\/14737175.2015.1088783","volume":"15","author":"R Bhidayasiri","year":"2015","unstructured":"Bhidayasiri R, Hattori N, Jeon B, Chen RS, Lee MK, Bajwa JA, Mok VC, Zhang B, Syamsudin T, Tan LC, Jamora RD, Pisarnpong A, Poewe W (2015) Asian perspectives on the recognition and management of levodopa \u201cwearing-off\u201d in Parkinson\u2019s disease. Expert Rev Neurother 15(11):1285\u20131297. https:\/\/doi.org\/10.1586\/14737175.2015.1088783","journal-title":"Expert Rev Neurother"},{"issue":"10291","key":"2914_CR6","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397(10291):2284\u20132303. https:\/\/doi.org\/10.1016\/S0140-6736(21)00218-X","journal-title":"Lancet"},{"key":"2914_CR7","unstructured":"Carbidopa and Levodopa (2024) Carbidopa and levodopa: effectiveness, side effects, alternatives in the real world. eHealthMe. A platform for the public to run phase IV clinical trial. https:\/\/www.ehealthme.com\/drug\/carbidopa-and-levodopa\/"},{"key":"2914_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106983","volume":"124","author":"S Caronni","year":"2024","unstructured":"Caronni S, Del Sorbo F, Barichella M, Fothergill-Misbah N, Denne T, Laguna J, Urasa S, Dekker MCJ, Akpalu A, Sarfo FS, Cham M, Pezzoli G, Cilia R (2024) Mucuna pruriens to treat Parkinson\u2019s disease in low-income countries: recommendations and practical guidelines from the farmer to clinical trials\u2014paving the way for future use in clinical practice. Parkinsonism Relat Disord 124:106983. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106983","journal-title":"Parkinsonism Relat Disord"},{"key":"2914_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jns.2016.04.001","volume":"365","author":"E Cassani","year":"2016","unstructured":"Cassani E, Cilia R, Laguna J, Barichella M, Contin M, Cereda E, Isaias IU, Sparvoli F, Akpalu A, Budu KO, Scarpa MT, Pezzoli G (2016) Mucuna pruriens for Parkinson\u2019s disease: low-cost preparation method, laboratory measures and pharmacokinetics profile. J Neurol Sci 365:175\u2013180. https:\/\/doi.org\/10.1016\/j.jns.2016.04.001","journal-title":"J Neurol Sci"},{"key":"2914_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/868062","volume":"2014","author":"NS Chauhan","year":"2014","unstructured":"Chauhan NS, Sharma V, Dixit VK, Thakur M (2014) A review on plants used for improvement of sexual performance and virility. Biomed Res Int 2014:868062. https:\/\/doi.org\/10.1155\/2014\/868062","journal-title":"Biomed Res Int"},{"issue":"5","key":"2914_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/WNL.0000000000004175","volume":"89","author":"R Cilia","year":"2017","unstructured":"Cilia R, Laguna J, Cassani E, Cereda E, Pozzi NG, Isaias IU, Contin M, Barichella M, Pezzoli G (2017) Mucuna pruriens in Parkinson disease: a double-blind, randomized, controlled, crossover study. Neurology 89(5):432\u2013438. https:\/\/doi.org\/10.1212\/WNL.0000000000004175","journal-title":"Neurology"},{"key":"2914_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.parkreldis.2018.01.014","volume":"49","author":"R Cilia","year":"2018","unstructured":"Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, Pezzoli G (2018) Daily intake of Mucuna pruriens in advanced Parkinson\u2019s disease: a 16-week, noninferiority, randomized, crossover, pilot study. Parkinsonism Relat Disord 49:60\u201366. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.01.014","journal-title":"Parkinsonism Relat Disord"},{"key":"2914_CR13","unstructured":"Clinical Pharmacology and Pharmacokinetics (2024) Clinical pharmacology and pharmacokinetics: questions and answers. (2022) European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-and-development\/scientific-guidelines\/clinical-pharmacology-pharmacokinetics\/clinical-pharmacology-pharmacokinetics-questions-answers"},{"key":"2914_CR14","doi-asserted-by":"publisher","unstructured":"Cohen PA, Avula B, Katragunta K, Khan I (2022) Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database. JAMA Neurol 79(10):1085\u20131086. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2184","DOI":"10.1001\/jamaneurol.2022.2184"},{"issue":"Suppl 2","key":"2914_CR15","doi-asserted-by":"publisher","first-page":"S253","DOI":"10.1007\/s00415-010-5728-8","volume":"257","author":"M Contin","year":"2010","unstructured":"Contin M, Martinelli P (2010) Pharmacokinetics of levodopa. J Neurol 257(Suppl 2):S253-261. https:\/\/doi.org\/10.1007\/s00415-010-5728-8","journal-title":"J Neurol"},{"issue":"5","key":"2914_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/WNF.0000000000000098","volume":"38","author":"M Contin","year":"2015","unstructured":"Contin M, Lopane G, Passini A, Poli F, Iannello C, Guarino M (2015) Mucuna pruriens in Parkinson disease: a kinetic-dynamic comparison with levodopa standard formulations. Clin Neuropharmacol 38(5):201\u2013203. https:\/\/doi.org\/10.1097\/WNF.0000000000000098","journal-title":"Clin Neuropharmacol"},{"key":"2914_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-024-01607-z","author":"S Das","year":"2024","unstructured":"Das S, Rajeswari VD, Venkatraman G, Ramanathan G (2024) Phytochemicals in Parkinson\u2019s disease: a pathway to neuroprotection and personalized medicine. Cell Biochem Biophys. https:\/\/doi.org\/10.1007\/s12013-024-01607-z","journal-title":"Cell Biochem Biophys"},{"key":"2914_CR18","doi-asserted-by":"publisher","unstructured":"Ferguson CC, Knol LL, Halli-Tierney A, Ellis AC (2019) Dietary supplement use is high among individuals with Parkinson disease. South Med J 112(12):621\u2013625. https:\/\/doi.org\/10.14423\/SMJ.0000000000001041","DOI":"10.14423\/SMJ.0000000000001041"},{"issue":"6","key":"2914_CR19","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/mdc3.14044","volume":"11","author":"SE Gandhi","year":"2024","unstructured":"Gandhi SE, Zerenner T, Nodehi A, Lawton MA, Marshall V, Al-Hajraf F, Grosset KA, Morris HR, Hu MT, Ben-Shlomo Y, Grosset DG (2024) Motor complications in Parkinson\u2019s disease: results from 3343 patients followed for up to 12 years. Mov Disord Clin Pract 11(6):686\u2013697. https:\/\/doi.org\/10.1002\/mdc3.14044","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"2914_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/mds.26050","volume":"30","author":"OS Gershanik","year":"2015","unstructured":"Gershanik OS (2015) Improving L-dopa therapy: the development of enzyme inhibitors. Mov Disord 30(1):103\u2013113. https:\/\/doi.org\/10.1002\/mds.26050","journal-title":"Mov Disord"},{"issue":"3","key":"2914_CR21","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3233\/JPD-213006","volume":"12","author":"ZHK Goh","year":"2022","unstructured":"Goh ZHK, Cheong JLY, Marras C, Tanner CM, Kasten M, Korczyn AD, Chahine L, Lo R, Noyce AJ, Movement Disorders Society Epidemiology Study G (2022) Surveying global availability of parkinson\u2019s disease treatment. J Parkinsons Dis 12(3):1023\u20131034. https:\/\/doi.org\/10.3233\/JPD-213006","journal-title":"J Parkinsons Dis"},{"key":"2914_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0072-9752(07)84032-2","volume":"84","author":"TD Halbig","year":"2007","unstructured":"Halbig TD, Koller WC (2007) Levodopa. Handb Clin Neurol 84:31\u201372. https:\/\/doi.org\/10.1016\/S0072-9752(07)84032-2","journal-title":"Handb Clin Neurol"},{"issue":"11","key":"2914_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1111\/jphp.13154","volume":"71","author":"JH Hughes","year":"2019","unstructured":"Hughes JH, Upton RN, Reuter SE, Phelps MA, Foster DJR (2019) Optimising time samples for determining area under the curve of pharmacokinetic data using non-compartmental analysis. J Pharm Pharmacol 71(11):1635\u20131644. https:\/\/doi.org\/10.1111\/jphp.13154","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"2914_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.14802\/jmd.21104","volume":"15","author":"P Jagota","year":"2022","unstructured":"Jagota P, Srivanitchapoom P, Petchrutchatachart S, Singmaneesakulchai S, Pisarnpong A, Lolekha P, Setthawatcharawanich S, Chairangsaris P, Limotai N, Mekawichai P, Panyakaew P, Phokaewvarangkul O, Sringean J, Pitakpatapee Y, LaPelle N, Martinez-Martin P, Ren X, Luo S, Stebbins GT, Goetz CG, Bhidayasiri R (2022) Validation of the Thai version of the movement disorder society-sponsored revision of the unified Parkinson\u2019s disease rating scale. J Mov Disord 15(2):151\u2013155. https:\/\/doi.org\/10.14802\/jmd.21104","journal-title":"J Mov Disord"},{"issue":"2","key":"2914_CR25","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JPD-130271","volume":"4","author":"O Jitkritsadakul","year":"2014","unstructured":"Jitkritsadakul O, Jagota P, Bhidayasiri R (2014) The Arizona sexual experiences scale: a validity and reliability assessment of the Thai translation (ASEX-Thai) in Parkinson\u2019s disease. J Parkinsons Dis 4(2):205\u2013210. https:\/\/doi.org\/10.3233\/JPD-130271","journal-title":"J Parkinsons Dis"},{"key":"2914_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-024-02871-2","author":"WH Jost","year":"2024","unstructured":"Jost WH (2024) Advanced therapy in advanced Parkinson\u2019s disease: money\u2019s too tight to mention. J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-024-02871-2","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"2914_CR27","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13596-013-0126-2","volume":"13","author":"S Kasture","year":"2013","unstructured":"Kasture S, Mohan M, Kasture V (2013) Mucuna pruriens seeds in treatment of Parkinson\u2019s disease: pharmacological review. Orient Pharm Exp Med 13(3):165\u2013174. https:\/\/doi.org\/10.1007\/s13596-013-0126-2","journal-title":"Orient Pharm Exp Med"},{"issue":"12","key":"2914_CR28","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1136\/jnnp.2003.028761","volume":"75","author":"R Katzenschlager","year":"2004","unstructured":"Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, Timmermann L, Van der Giessen R, Lees AJ (2004) Mucuna pruriens in Parkinson\u2019s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 75(12):1672\u20131677. https:\/\/doi.org\/10.1136\/jnnp.2003.028761","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2914_CR29","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/BF02236639","volume":"43","author":"CH Knowles","year":"2000","unstructured":"Knowles CH, Eccersley AJ, Scott SM, Walker SM, Reeves B, Lunniss PJ (2000) Linear discriminant analysis of symptoms in patients with chronic constipation: validation of a new scoring system (KESS). Dis Colon Rectum 43(10):1419\u20131426. https:\/\/doi.org\/10.1007\/BF02236639","journal-title":"Dis Colon Rectum"},{"issue":"4","key":"2914_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/s2225-4110(16)30119-5","volume":"2","author":"LR Lampariello","year":"2012","unstructured":"Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G (2012) The magic velvet bean of Mucuna pruriens. J Tradit Complement Med 2(4):331\u2013339. https:\/\/doi.org\/10.1016\/s2225-4110(16)30119-5","journal-title":"J Tradit Complement Med"},{"key":"2914_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/840247","volume":"2012","author":"CA Lieu","year":"2012","unstructured":"Lieu CA, Venkiteswaran K, Gilmour TP, Rao AN, Petticoffer AC, Gilbert EV, Deogaonkar M, Manyam BV, Subramanian T (2012) The Antiparkinsonian and antidyskinetic mechanisms of Mucuna pruriens in the MPTP-treated nonhuman primate. Evid Based Complement Alternat Med 2012:840247. https:\/\/doi.org\/10.1155\/2012\/840247","journal-title":"Evid Based Complement Alternat Med"},{"issue":"1","key":"2914_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mds.870050112","volume":"5","author":"BV Manyam","year":"1990","unstructured":"Manyam BV (1990) Paralysis agitans and levodopa in \u201cAyurveda\u201d: ancient Indian medical treatise. Mov Disord 5(1):47\u201348. https:\/\/doi.org\/10.1002\/mds.870050112","journal-title":"Mov Disord"},{"issue":"2","key":"2914_CR33","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/s0022-510x(00)00329-4","volume":"176","author":"N Nagashayana","year":"2000","unstructured":"Nagashayana N, Sankarankutty P, Nampoothiri MR, Mohan PK, Mohanakumar KP (2000) Association of L-DOPA with recovery following Ayurveda medication in Parkinson\u2019s disease. J Neurol Sci 176(2):124\u2013127. https:\/\/doi.org\/10.1016\/s0022-510x(00)00329-4","journal-title":"J Neurol Sci"},{"key":"2914_CR34","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jns.2016.01.005","volume":"361","author":"Y Nagashima","year":"2016","unstructured":"Nagashima Y, Kondo T, Sakata M, Koh J, Ito H (2016) Effects of soybean ingestion on pharmacokinetics of levodopa and motor symptoms of Parkinson\u2019s disease\u2013in relation to the effects of Mucuna pruriens. J Neurol Sci 361:229\u2013234. https:\/\/doi.org\/10.1016\/j.jns.2016.01.005","journal-title":"J Neurol Sci"},{"issue":"6","key":"2914_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.890","volume":"9","author":"O Olafuyi","year":"2021","unstructured":"Olafuyi O, Parekh N, Wright J, Koenig J (2021) Inter-ethnic differences in pharmacokinetics-is there more that unites than divides? Pharmacol Res Perspect 9(6):e00890. https:\/\/doi.org\/10.1002\/prp2.890","journal-title":"Pharmacol Res Perspect"},{"issue":"5","key":"2914_CR36","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/mds.25420","volume":"28","author":"S Ovallath","year":"2013","unstructured":"Ovallath S, Deepa P (2013) The history of Parkinsonism: descriptions in ancient Indian medical literature. Mov Disord 28(5):566\u2013568. https:\/\/doi.org\/10.1002\/mds.25420","journal-title":"Mov Disord"},{"issue":"12","key":"2914_CR37","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601. https:\/\/doi.org\/10.1002\/mds.26424","journal-title":"Mov Disord"},{"key":"2914_CR38","doi-asserted-by":"publisher","first-page":"11078","DOI":"10.1038\/srep11078","volume":"5","author":"H Pulikkalpura","year":"2015","unstructured":"Pulikkalpura H, Kurup R, Mathew PJ, Baby S (2015) Levodopa in Mucuna pruriens and its degradation. Sci Rep 5:11078. https:\/\/doi.org\/10.1038\/srep11078","journal-title":"Sci Rep"},{"issue":"12","key":"2914_CR39","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s13205-020-02532-7","volume":"10","author":"SN Rai","year":"2020","unstructured":"Rai SN, Chaturvedi VK, Singh P, Singh BK, Singh MP (2020) Mucuna pruriens in Parkinson\u2019s and in some other diseases: recent advancement and future prospective. 3 Biotech 10(12):522. https:\/\/doi.org\/10.1007\/s13205-020-02532-7","journal-title":"3 Biotech"},{"issue":"20","key":"2914_CR40","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.2169\/internalmedicine.3171-23","volume":"63","author":"M Sakata","year":"2024","unstructured":"Sakata M, Miyamoto K, Koh J, Nagashima Y, Kondo T, Ito H (2024) Japanese Mucuna pruriens (Hasshou Beans) showed fast-acting and long-lasting effects in Parkinson\u2019s disease. Intern Med 63(20):2773\u20132779. https:\/\/doi.org\/10.2169\/internalmedicine.3171-23","journal-title":"Intern Med"},{"issue":"1","key":"2914_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054655","volume":"8","author":"AP Singh","year":"2013","unstructured":"Singh AP, Sarkar S, Tripathi M, Rajender S (2013) Mucuna pruriens and its major constituent L-DOPA recover spermatogenic loss by combating ROS, loss of mitochondrial membrane potential and apoptosis. PLoS ONE 8(1):e54655. https:\/\/doi.org\/10.1371\/journal.pone.0054655","journal-title":"PLoS ONE"},{"key":"2914_CR42","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/978-3-319-68864-0_4","volume-title":"Drug discovery and evaluation: methods in clinical pharmacology","author":"SG Woolfrey","year":"2020","unstructured":"Woolfrey SG, Morrison JG (2020) Pharmacokinetic aspects of multiple dose studies. In: Hock FJ, Gralinski MR (eds) Drug discovery and evaluation: methods in clinical pharmacology. Springer, Cham, pp 683\u2013693. https:\/\/doi.org\/10.1007\/978-3-319-68864-0_4"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-02914-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-02914-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:44:26Z","timestamp":1763563466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-02914-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":42,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["2914"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-02914-2","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"9 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}